See more : Pure Storage, Inc. (PSTG) Income Statement Analysis – Financial Results
Complete financial analysis of Nuvation Bio Inc. (NUVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nuvation Bio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Astro Communications, Inc. (ASTO) Income Statement Analysis – Financial Results
- Garden Stage Limited Ordinary Shares (GSIW) Income Statement Analysis – Financial Results
- Phol Dhanya Public Company Limited (PHOL.BK) Income Statement Analysis – Financial Results
- Ascopiave S.p.A. (ASCOF) Income Statement Analysis – Financial Results
- Syngene International Limited (SYNGENE.NS) Income Statement Analysis – Financial Results
Nuvation Bio Inc. (NUVB)
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 222.00K | 484.00K | 368.00K | 103.00K | 0.00 | 0.00 |
| Gross Profit | -222.00K | -484.00K | -368.00K | -103.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 71.29M | 87.82M | 69.04M | 32.60M | 25.11M | 482.67K |
| General & Administrative | 26.83M | 31.92M | 24.28M | 10.95M | 6.59M | 509.33K |
| Selling & Marketing | 1.70M | 0.00 | 0.00 | 0.00 | 400.00 | 0.00 |
| SG&A | 28.53M | 31.92M | 24.28M | 10.95M | 6.99M | 509.33K |
| Other Expenses | 0.00 | -872.00K | -644.00K | -271.00K | 0.00 | 0.00 |
| Operating Expenses | 99.82M | 119.73M | 93.32M | 43.55M | 32.18M | 992.00K |
| Cost & Expenses | 99.82M | 119.73M | 93.32M | 43.55M | 32.18M | 992.00K |
| Interest Income | 24.61M | 7.45M | 2.96M | 1.95M | 1.37K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 222.00K | 484.00K | 368.00K | 103.00K | 13.00K | 992.00K |
| EBITDA | -99.60M | -119.54M | -89.35M | -43.45M | -32.09M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -99.82M | -119.73M | -93.32M | -43.55M | -32.10M | -992.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 24.02M | 15.54M | 6.47M | 1.89M | -1.45M | 0.00 |
| Income Before Tax | -75.80M | -104.20M | -86.85M | -41.66M | -33.55M | -992.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.54M | -7.11M | -2.16M | 0.00 | 0.00 |
| Net Income | -75.80M | -88.66M | -79.73M | -39.50M | -33.55M | -992.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.35 | -0.41 | -0.40 | -0.40 | -0.16 | -0.01 |
| EPS Diluted | -0.35 | -0.41 | -0.40 | -0.40 | -0.16 | -0.01 |
| Weighted Avg Shares Out | 218.88M | 216.72M | 197.89M | 97.53M | 206.67M | 80.99M |
| Weighted Avg Shares Out (Dil) | 218.88M | 216.72M | 197.89M | 97.53M | 206.67M | 80.99M |
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in...
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years...
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational...
Nuvation Bio to Present at the Cantor Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at...
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced multiple updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study has...
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major...
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and...
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its investigational next-generation...
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive...
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024,...
Source: https://incomestatements.info
Category: Stock Reports